King's College London

Research portal

The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review

Research output: Contribution to journalArticle

E. Copson, A.M. Shaaban, T. Maishman, P.M. Moseley, H. McKenzie, J. Bradbury, A. Borley, M. Brzezinska, S.Y.T. Chan, J. Ching, R.I. Cutress, I. Danial, B. Dall, M. Kerin, A.J. Lowery, I.R. Macpherson, L. Romics, E. Sawyer, N. Sharmat, T. Sircar & 7 more R. Vidya, Y. Pan, D. Rea, UK Inflammatory Breast Cancer Consortium, L. Jones, D.M. Eccles, F. Berditchevski

Original languageEnglish
JournalBREAST
Early online date15 Sep 2018
DOIs
Publication statusE-pub ahead of print - 15 Sep 2018

Documents

King's Authors

  • UK Inflammatory Breast Cancer Consortium

Abstract

Objectives Inflammatory Breast cancer (IBC) is a rare but aggressive form of breast cancer. Its incidence and behaviour in the UK is poorly characterised. We collected retrospective data from hospitals in the UK and Ireland to describe the presentation, pathology, treatment and clinical course of IBC in the UK. Materials and methods Patients with IBC diagnosed between 1997–2014 at fourteen UK and Irish hospitals were identified from local breast unit databases. Patient characteristics, tumour pathology and stage, and details of surgical, systemic and radiotherapy treatment and follow-up data were collected from electronic patient records and medical notes. Result This retrospective review identified 445 patients with IBC accounting for 0.4–1.8% of invasive breast cancer cases. Median follow-up was 4.2 years. 53.2% of tumours were grade 3, 56.2% were oestrogen receptor positive, 31.3% were HER2 positive and 25.1% were triple negative. 20.7% of patients had distant metastases at presentation. Despite trimodality treatment in 86.4%, 40.1% of stage III patients developed distant metastases. Five-year overall survival (OS) was 61.0% for stage III and 21.4% for stage IV patients. Conclusions This is the largest series of UK IBC patients reported to date. It indicates a lower incidence than in American series, but confirms that IBC has a high risk of recurrence with poor survival despite contemporary multi-modality therapy. A national strategy is required to facilitate translational research into this aggressive disease.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454